Envarsus XL Immunosuppression Following Liver Transplantation

Completed · Phase 2

Conditions studied: Recipients of Liver Transplant

In brief

The standard immunosuppressive regimen for liver transplantation includes twice daily tacrolimus (Prograf). In other transplantation models, there are potential benefits to extended release formulations as lower peak concentrations are thought to have lower rates of nephrotoxicity. Additionally, compliance with once daily medications is felt to be easier than twice daily medications. Our aim is to look at our prospective liver transplant group and see if once daily tacrolimus (Envarsus XR) results in improved renal function as well as improved health care quality of life.

Key facts

Study ID
NCT03828058
Run by
Methodist Healthcare - Memphis
People needed
110
Starts
2019-04-01
Expected to finish
2020-12-31
Last updated by the study team
2021-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.